3PO

Research use only, not for human use.

3PO is a small-molecule inhibitor of PFKFB3 (IC50: 22.9 μM), inhibiting the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50: 1.4-24 μM).

3PO is a small-molecule inhibitor of PFKFB3 (IC50: 22.9 μM), inhibiting the proliferation of several human malignant hematopoietic and adenocarcinoma cell lines (IC50: 1.4-24 μM). It suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.

3PO (0-33 μM; 0-36 h) inhibits Jurkat cells proliferation by influence cell cycle.3PO (10 μM/L; 0-36 h) suppresses glycolytic flux to lactate in Jurkat cells.3PO (10 μM/L; 0-36 h) inhibits cellular proliferation of transformed tumor cell lines. Cell Proliferation Assay Cell Line:Jurkat cells Concentration:0.3, 1, 3, 10 and 33 μM Incubation Time:0, 4, 8, 16, 24 and 36 hours Result:Inhibited Jurkat T cells proliferation by G2-M phase cell cycle arrest.Cell Viability Assay Cell Line:Jurkat cells Concentration:0.3, 1, 3, 10 and 33 μM Incubation Time:0, 4, 8, 16, 24 and 36 hours Result:Decreased lactate secretion, NADH, NAD+ and ATP in Jurkat cells.Cell Proliferation Assay Cell Line:Jurkat, K562, HL-60, MDA-MB231, HL-60, HeLa, Melanoma and Lewis Lung Concentration:0-20 μM Incubation Time:0, 4, 8, 16, 24 and 36 hours Result:Inhibited solid tumor and hematologic cell lines with IC50s of 1.4-24 μM/L.

3PO (0.07 mg/g; i.p. once per day for 14 days) inhibits the growth of Lewis lung carcinoma xenografts in C57Bl/6 mice.3PO (0.07 mg/g; i.p. three sequential daily injections followed by 3 off days for 14 days) inhibits the tumor growth in BALB/c athymic mice.3PO (0.07 mg/g; i.p. two daily injections followed a 7-day rest for 14 days) inhibits the tumor growth in BALB/c athymic mice.3PO (0.07 mg/g; i.p. once) inhibits Fru-2,6-BP and glucose uptake in C57Bl/6 mice. Animal Model:Female C57Bl/6 mice with Lewis lung carcinoma xenografts Dosage:0.07 mg/g Administration:Intraperitoneal injection; 0.07 mg/g once a day; for 14 days Result:Suppressed the growth of Lewis lung carcinoma xenografts in C57Bl/6 mice compared to the control group.Animal Model:Female BALB/c athymic mice with MDA-MB231 human breast adenocarcinoma xenografts Dosage:0.07 mg/g Administration:Intraperitoneal injection; 0.07 mg/g three sequential daily injections of either DMSO or 3PO followed by 3 off days; for 14 days Result:Suppressed xenograft tumorigenic growth of MDA-MB231 cells compared with the controls.Animal Model:Female BALB/c athymic mice with HL-60 leukemia xenografts Dosage:0.07 mg/g Administration:Intraperitoneal injection; 0.07 mg/g two daily injections followed a 7-day rest; for 14 days Result:Suppressed xenograft tumorigenic growth of HL-60 leukemia compared with the controls, especially from the second administration cycle.Animal Model:Female C57Bl/6 mice with Lewis lung carcinoma xenografts Dosage:0.07 mg/g Administration:Intraperitoneal injection; once Result:Decreased Fru-2,6-BP and glucose uptake in C57Bl/6 mice compared to control group.

——

Cytoskeleton/Cell Adhesion Molecules

Glucokinase

PFKFB3

——

——

18550-98-6

210.23

C13H10N2O

>98% (HPLC)

DMSO:113mg/ml（537.51mM）;Ethanol:11 mg/mL (52.32 mM);Water:Insoluble

O=C(/C=C/c1cnccc1)c1ccncc1

——

(-20℃)

With Ice Pack

≥ 2 years